SCPH Earnings Prediction
The chart below shows how SCPH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SCPH sees a +3.22% change in stock price 10 days leading up to the earnings, and a +6.60% change 10 days following the report. On the earnings day itself, the stock moves by +0.59%. This data can give you a slight idea of what to expect for the next quarter's release.
SCPH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
10.03M
164.12%
24.48%
Gross Margin
66.98%
-6.43%
-6.24%
Operating Margin
-180.99%
-53.70%
1.01%
Net Margin
-350.14%
-14.98%
65.01%
EPS
-0.75
-87.50%
70.45%
No Data Available
SCPH Earnings Analysis
scPharmaceuticals Inc. Common Stock Corporation (SCPH.O) Earnings Conference Call
Positive
Net Revenue Increase: In the third quarter of 2024, we generated net revenue of $10 million, representing an approximately 24% increase in net revenue from the second quarter of 2024.
Product Revenue Increase: Product revenues were $10 million for the third quarter of 2024 compared to $3.8 million for the third quarter of 2023.
Product Revenue Increase: The increase in product revenues for the quarter ended September 30, 2024, was due to an increase in demand of FUROSCIX further into commercial launch and related manufacturing costs.
Furoscix Dose Increase: We filled approximately 10,800 doses of FUROSCIX, a 16% increase from the previous quarter.
Cash and Cash Equivalents Increase: We ended the third quarter of 2024 with $91.5 million in cash and cash equivalents compared to $76 million in cash and cash equivalents as of December 31, 2023.
Negative
Q3 2024 Revenue Disappointment: Net revenue for Q3 2024 was $10 million, which is a disappointment given the strong demand at the beginning of the quarter, representing only a 24% increase from Q2 2024.
Gross Net Discount Analysis: Gross net discount was approximately 15.7%, just above the high end of the guided range of 10% to 15%, indicating higher costs than anticipated.
Net Loss Increase: The company reported a net loss of $35.1 million for Q3 2024, compared to a net loss of $15.6 million for Q3 2023, highlighting a significant deterioration in financial performance.
SG&A Expense Increase: Selling, general, and administrative expenses increased to $21.3 million for Q3 2024, up from $14.1 million in Q3 2023, reflecting rising operational costs.
R&D Expense Increase: Research and development expenses rose to $3.5 million for Q3 2024, compared to $3.4 million for Q3 2023, indicating increased investment without corresponding returns.
SCPH FAQs
How does SCPH typically perform around its earnings report dates?
Is scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SCPH Earning Call Sentiment
scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SCPH.O
1.23%Positive
The earnings call presents a mixed picture. While there are positive developments like revenue growth and cash position improvement, significant net losses and regulatory risks pose challenges. The Q&A section reveals some optimism, but management's unclear responses about the slower quarter-end and coverage gap issues raise concerns. The transformative financing and market expansion efforts are positives, yet the financial risks and competitive pressures balance the sentiment. Overall, the stock price is likely to remain stable in the short term, leading to a neutral prediction.
